Climb Bio Inc (NASDAQ: CLYM) kicked off on Monday, up 14.49% from the previous trading day, before settling in for the closing price of $4.28. Over the past 52 weeks, CLYM has traded in a range of $1.05-$4.82.
Annual sales at Healthcare sector company slipped by -40.44% over the past five years. While this was happening, its average annual earnings per share was recorded 46.48%. With a float of $62.43 million, this company’s outstanding shares have now reached $68.18 million.
Climb Bio Inc (CLYM) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Climb Bio Inc is 8.44%, while institutional ownership is 45.75%. The most recent insider transaction that took place on Dec 11 ’25, was worth 464,556. In this transaction Director of this company bought 213,099 shares at a rate of $2.18, taking the stock ownership to the 3,294,856 shares. Before that another transaction happened on Dec 12 ’25, when Company’s Director bought 101,462 for $2.86, making the entire transaction worth $290,181. This insider now owns 3,396,318 shares in total.
Climb Bio Inc (CLYM) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.04 earnings per share (EPS), higher than consensus estimate (set at -0.15) by 0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.57% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
Take a look at Climb Bio Inc’s (CLYM) current performance indicators. Last quarter, stock had a quick ratio of 18.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.75, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.85 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
Climb Bio Inc (NASDAQ: CLYM) saw its 5-day average volume 2.69 million, a positive change from its year-to-date volume of 0.6 million. As of the previous 9 days, the stock’s Stochastic %D was 88.97%.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 99.16%, which indicates a significant increase from 99.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.51 in the past 14 days, which was higher than the 0.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.24, while its 200-day Moving Average is $1.72. Nevertheless, the first resistance level for the watch stands at $5.13 in the near term. At $5.37, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.80. If the price goes on to break the first support level at $4.46, it is likely to go to the next support level at $4.03. Assuming the price breaks the second support level, the third support level stands at $3.79.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
The company with the Market Capitalisation of 334.10 million has total of 68,184K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -73,900 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -12,890 K.
